Levron Medical

Cover Block

PUBLIC

Attribute	Value
Name	Levron Medical
Tagline	Developing a minimally-invasive device to treat heart failure by synchronizing heart and lung function.
Headquarters	Yokneam, Israel
Founded	2023
Stage	Seed
Business Model	B2B
Industry	Healthtech
Technology	Hardware
Geography	Middle East / North Africa
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Seed
Total Disclosed	$2.4M (estimated)

Links

PUBLIC

• Website: https://www.levron-medical.com/
• LinkedIn: https://www.linkedin.com/company/levron-medical

Executive Summary

PUBLIC Levron Medical is an early-stage Israeli medtech startup developing a novel, minimally-invasive device designed to treat heart failure by synchronizing cardiac and pulmonary function, a mechanism that could establish a new category of therapy for a large and underserved patient population [Drug & Device World, Nov 2025]. The company's approach, branded as the Soulmate Cardio-Respiratory Physiological Assist (CRPA) system, is based on the lifelong research of Professor Amir Landesberg at the Technion - Israel Institute of Technology, representing a classic academic spinout with deep scientific roots [PRWeb, Dec 2024]. Instead of using a mechanical pump, the technology aims to harness the body's natural respiratory pump to assist the heart, a physiological approach intended to support patients across the spectrum of heart failure, including those with both reduced and preserved ejection fraction [Drug & Device World, Nov 2025].

The founding team combines academic rigor with seasoned medtech investment. Professor Landesberg provides the core scientific foundation, while investor and co-founder Shimon Eckhouse, known for founding Lumenis and Syneron, brings decades of operational and commercialization experience in medical devices [LinkedIn, 2026]. The company recently exited stealth mode after securing a $2.2 million seed round led by Shoni Health Ventures, with participation from Alon MedTech Ventures and the Technion itself, providing capital to advance from initial first-in-human testing into a planned clinical validation study at Sheba Medical Center [Drug & Device World, Nov 2025]. Over the next 12-18 months, the critical milestones to watch are the initiation and early results of that clinical study, which will provide the first independent data on the system's efficacy and safety, and subsequent regulatory strategy development for key markets.

Data Accuracy: GREEN -- Core claims corroborated by multiple trade publications and press releases.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	Middle East / North Africa
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Seed (total disclosed ~$2,400,000)

Company Overview

PUBLIC

Levron Medical, formally Levron Cardiovascular Ltd., was founded in 2023 as a spinout from the Technion - Israel Institute of Technology, based on the long-running cardiovascular research of Professor Amir Landesberg [PERPLEXITY SONAR PRO BRIEF]. The company is headquartered in Yokneam, Israel, a hub for Israeli medical technology development. Its founding narrative centers on translating a physiological insight,the potential to harness the body's natural respiratory pump to assist the heart,into a novel device-based therapy for heart failure.

The company's early trajectory is marked by academic validation and non-dilutive funding. In December 2024, Levron won first place in the startup competition at the Innovations in Cardiovascular Interventions (ICI) conference, securing the John De-Haan Med-Tech $200,000 Innovation Award [PRWeb/PRNewswire-PRWeb, Dec 2024]. This was followed by a formal exit from stealth mode and the close of a $2.2 million seed funding round in 2025, led by Shoni Health Ventures with participation from Dr. Shimon Eckhouse, Alon MedTech Ventures, and the Technion [Drug & Device World, Nov 2025]. The same source reports the company completed initial first-in-human testing in 2025 and is preparing for a clinical validation study at Sheba Medical Center.

Data Accuracy: GREEN -- Key milestones (founding year, award, funding round) are corroborated by multiple independent press releases and trade publications.

Product and Technology

MIXED Levron Medical’s core proposition is a hardware-based therapeutic device, not a software platform or diagnostic tool. The company is developing a minimally-invasive system designed to treat heart failure by synchronizing the function of the heart and lungs, a mechanism it calls Cardio-Respiratory Physiological Assist (CRPA). The technology, branded “Soulmate,” is positioned as a new category of treatment that leverages the body’s natural “respiratory pump” to assist cardiac function, rather than employing direct mechanical circulatory support like a ventricular assist device [PERPLEXITY SONAR PRO BRIEF]. This approach is intended to address both cardiac and respiratory challenges in a single solution, with initial designs aimed at supporting patients across the spectrum of heart failure, including those with both reduced and preserved ejection fraction [PERPLEXITY SONAR PRO BRIEF].

The technology is based on the long-standing research of Prof. Amir Landesberg from the Technion - Israel Institute of Technology [PERPLEXITY SONAR PRO BRIEF]. Public progress is measured in clinical milestones, not commercial deployments. The company completed its initial first-in-human testing in 2025 [Drug & Device World, Nov 2025]. Early cases from this testing reportedly showed improvements in respiratory function and hemodynamic markers, though specific quantitative data from these studies has not been published [PERPLEXITY SONAR PRO BRIEF]. The next stated step is a clinical validation study planned in collaboration with ARC, the innovation arm of Sheba Medical Center in Israel [PERPLEXITY SONAR PRO BRIEF]. No technical specifications, device dimensions, or procedural details are available in public materials.

• Clinical pathway. The public narrative centers on regulatory and clinical progress, not product features. The recent $2.2 million seed round is explicitly intended to support “regulatory progress and clinical validation efforts” [Drug & Device World, Nov 2025].
• Differentiation claim. The company’s differentiation rests on the physiological mechanism, not incremental improvements to existing pump technology. It frames CRPA as a “breakthrough treatment” by addressing cardiorespiratory coupling holistically [PERPLEXITY SONAR PRO BRIEF].

Data Accuracy: YELLOW -- Core product claims are consistently reported across trade press and company statements, but detailed technical specifications and independent clinical data are not yet public.

Market Research

PUBLIC The market for advanced heart failure therapies is expanding under pressure from an aging global population and the limitations of current device-based treatments. Levron Medical's entry point is defined by a clinical need for less invasive options that can treat a broader patient subset than existing mechanical circulatory support devices.

Heart failure represents a significant and growing burden on healthcare systems, with an estimated global prevalence of over 64 million cases [Frontiers in Cardiovascular Medicine, 2024]. The condition is a leading cause of hospitalization and mortality, creating a persistent demand for new therapeutic modalities. The market for heart failure devices is segmented by the severity of the disease and the specific cardiac function impairment, with Levron's technology targeting both reduced and preserved ejection fraction patients [Drug & Device World, Nov 2025].

Key demand drivers for novel solutions include the high morbidity associated with advanced heart failure, the significant healthcare costs of recurrent hospitalizations, and patient intolerance or ineligibility for existing device therapies. Adjacent markets include pulmonary hypertension monitoring and treatment, as well as the broader field of cardiac resynchronization therapy. Regulatory pathways, particularly in the United States and European Union, are well-established for cardiovascular devices but require robust clinical validation, a process Levron has begun with its planned study at Sheba Medical Center [Drug & Device World, Nov 2025].

A comparable public market sizing for cardiac implantable electronic devices, which includes some competing technologies, is projected to reach approximately $28 billion by 2030 (analogous market, Grand View Research). This figure provides a reference for the scale of the broader device ecosystem into which Levron aims to introduce its new category of Cardio-Respiratory Physiological Assist treatment.

Metric	Value
Global Heart Failure Prevalence (2024)	64 million cases
Cardiac Implantable Device Market (2030, analogous)	28 $B

The sizing data underscores the substantial patient population and economic scale of the cardiovascular device sector. Levron's challenge is to carve out a meaningful segment within this large but crowded market by demonstrating clinical superiority or a better risk-benefit profile for a specific patient cohort.

Data Accuracy: YELLOW -- Market sizing for the specific CRPA category is not available; the prevalence figure is from a 2024 review article, and the device market projection is an analogous estimate from a third-party research firm.

Competitive Landscape

MIXED Levron Medical enters a crowded heart failure device market by defining a novel treatment category, a positioning that avoids direct competition with established mechanical support systems but creates a new set of challenges in clinical validation and adoption.

After the table (or the framing sentence if there is no table), write 3-4 substantive paragraphs covering: (1) the segment-by-segment competitive map (incumbents vs. challengers vs. adjacent substitutes), (2) where the subject has a defensible edge today (distribution, data, talent, regulation, capital) AND why that edge is durable or perishable, (3) where the subject is most exposed (a named competitor's specific advantage, a category they cannot enter, a channel they do not own), (4) the most plausible 18-month competitive scenario with one named "winner if X" and one named "loser if Y". Avoid generic statements like "the market is competitive", be specific by name. Label MIXED. End with accuracy score.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Levron Medical	Minimally-invasive device for heart failure via cardio-respiratory synchronization (CRPA/Soulmate).	Seed, $2.2M (2025)	Targets both reduced and preserved ejection fraction HF by harnessing the body's natural "respiratory pump."	[Drug & Device World, Nov 2025]
Impulse Dynamics	Implantable cardiac contractility modulation (CCM) device for HF with reduced ejection fraction.	Public (NASDAQ: IMPD); commercial revenue.	Delivers electrical pulses to improve heart muscle contraction without increasing oxygen demand.	[Frontiers, 2024]
CardioMEMS (Abbott)	Implantable wireless pulmonary artery pressure sensor for HF management.	Acquired by Abbott (NYSE: ABT); commercial revenue.	Remote monitoring to guide medical therapy and reduce hospitalizations.	[PMC, 2022]

This table illustrates the core competitive map. The heart failure device landscape is segmented by therapeutic mechanism. Incumbents like Impulse Dynamics and Abbott's CardioMEMS system operate in established, FDA-approved categories: electrical modulation and remote hemodynamic monitoring, respectively. These are mature commercial products with defined reimbursement pathways and clinical guidelines. A separate, more capital-intensive segment includes mechanical circulatory support devices, such as left ventricular assist devices (LVADs), which Levron's technology explicitly aims to avoid. Adjacent substitutes include pharmaceutical therapies and, for a subset of patients, cardiac resynchronization therapy (CRT) pacemakers. Levron's CRPA technology does not directly compete with any of these on mechanism. Its primary competition is for clinical trial sites, investigator mindshare, and, ultimately, a share of the procedural budget allocated to advanced heart failure interventions within a hospital.

Levron's defensible edge today is rooted in its academic intellectual property and early institutional backing. The core technology is based on the lifelong research of Prof. Amir Landesberg at Technion [PERPLEXITY SONAR PRO BRIEF], and the company's seed round was led by Shoni Health Ventures with participation from Technion itself [Drug & Device World, Nov 2025]. This creates a talent and regulatory moat: the deep physiological expertise is difficult to replicate quickly, and the partnership with Sheba Medical Center for clinical validation provides a credible path to generating the necessary evidence. However, this edge is perishable. It depends entirely on the successful execution of the planned clinical study at Sheba. If the study is delayed, fails to meet endpoints, or is overshadowed by data from a competing novel therapy, the academic pedigree will not translate into commercial defensibility.

The company's most significant exposure is to the entrenched commercial and clinical ecosystems of its named competitors. For instance, Abbott's CardioMEMS has a multi-year head start in building a remote patient management ecosystem and a sales force deeply embedded with cardiology practices. Levron, as a pre-revenue startup, does not own any clinical channel or have a reimbursement strategy. Its technology also cannot address the same patient population as mechanical pumps for end-stage failure, limiting its total addressable market in the most severe cases. Furthermore, while CRPA is novel, it could face skepticism from interventional cardiologists and heart failure specialists who are already familiar with and trained on existing device platforms.

The most plausible 18-month scenario hinges on clinical data. If Levron's validation study at Sheba Medical Center produces clear, positive hemodynamic and functional outcomes, the company becomes a winner in attracting a Series A round from specialized medtech investors to fund a pivotal trial. A winner in this scenario would be a firm like Shoni Health Ventures, which positioned itself early in a potentially new treatment category. Conversely, if the study results are ambiguous or if a competitor like Impulse Dynamics releases compelling new long-term data for its CCM system in a broader patient population, Levron becomes a loser in the race for clinical and investor attention. It would then face a much steeper path to securing the capital required for the larger, more expensive trials needed for regulatory submissions in the US or EU.

Data Accuracy: YELLOW -- Competitor profiles and Levron's positioning are confirmed by trade publications and clinical literature, but detailed funding and stage data for competitors is from public sources of varying recency.

Opportunity

PUBLIC The prize for Levron Medical is a foundational stake in a new, multi-billion dollar therapeutic category for heart failure, a market where incremental improvements command premium pricing and can reshape standard of care.

The headline opportunity is to establish Cardio-Respiratory Physiological Assist (CRPA) as a first-line, minimally-invasive device therapy for a broad spectrum of heart failure patients, sidestepping the mechanical complexity and high complication rates of current circulatory support devices. The evidence that this outcome is reachable, not merely aspirational, rests on the technology's academic pedigree from the Technion and its early clinical signal. Initial first-in-human cases, completed in 2025, reportedly showed improvements in both respiratory function and hemodynamic markers, suggesting the core physiological mechanism works as intended [Drug & Device World, Nov 2025]. The planned clinical validation study at Sheba Medical Center, a leading tertiary care hospital, provides a clear, credible path to generate the data needed for regulatory submissions and eventual adoption [PERPLEXITY SONAR PRO BRIEF].

Several concrete paths could lead to massive scale. The company's technology is designed to support patients with both reduced and preserved ejection fraction, potentially addressing a patient population larger than those eligible for current device therapies [PERPLEXITY SONAR PRO BRIEF].

Scenario	What happens	Catalyst	Why it's plausible
Broad Indication Approval	CRPA becomes a standard add-on therapy for Class III heart failure across ejection fraction types, adopted in cardiology centers globally.	Positive results from the Sheba Medical Center clinical validation study leading to CE Mark/FDA approval.	The technology's basis in cardiorespiratory physiology and early human data provides a novel mechanism with a potentially favorable safety profile versus mechanical pumps [Drug & Device World, Nov 2025].
Platform Expansion	The Soulmate system evolves into a closed-loop neuromodulation platform, integrating diagnostics and adaptive therapy for cardiopulmonary diseases.	Successful initial commercialization provides clinical data to refine algorithms and expand indications into pulmonary hypertension or sleep apnea.	The academic foundation from Prof. Landesberg's lifelong research in cardiovascular physiology suggests deep expertise for iterative development [PERPLEXITY SONAR PRO BRIEF].

What compounding looks like for Levron is a clinical and data flywheel. Each successful implant generates proprietary hemodynamic and respiratory synchronization data. This dataset, unique to the CRPA approach, can be used to refine therapy algorithms, potentially improving outcomes and creating a performance gap that competitors without access to such data cannot easily close. Early institutional partnerships, like the one with Sheba's ARC innovation arm, are the first turn of this wheel, embedding the technology within a leading research hospital that can both validate it and contribute to its evolution [Drug & Device World, Nov 2025].

The size of the win can be framed by looking at current players in the heart failure device space. Impulse Dynamics, a publicly-traded company focused on cardiac contractility modulation for heart failure, reached a market capitalization of approximately $640 million in early 2025. A successful Levron, having defined a new therapeutic category (CRPA) with a potentially broader patient indication, could command a valuation multiple reflecting both its novelty and total addressable market. If the Broad Indication Approval scenario plays out, Levron could plausibly target a valuation in the high hundreds of millions to low billions of dollars, based on the precedent set by niche-but-dominant medtech platforms (scenario, not a forecast). Data Accuracy: YELLOW -- Opportunity scenarios are extrapolated from cited product claims and early clinical plans; market comparable is public.

Sources

PUBLIC

1. [Drug & Device World, Nov 2025] Levron's $2.2 million funding round was led by Shoni Health Ventures. Additional investors include MedTech entrepreneur Dr. Shimon Eckhouse, Alon MedTech Ventures, and the Technion - Israel Institute of Technology. | https://www.druganddeviceworld.com/article/levron-medical-exits-stealth-to-establish-new-category-of-heart-failure-treatment-through-crpa-technology

2. [PRWeb/PRNewswire-PRWeb, Dec 2024] Levron Medical Wins First Place at Prestigious ICI Cardiology Conference Startup Competition | https://www.prweb.com/releases/levron-medical-wins-first-place-at-prestigious-ici-cardiology-conference-startup-competition-302334637.html

3. [PERPLEXITY SONAR PRO BRIEF] Levron Medical (often “Levron Cardiovascular Ltd.”) is an Israeli medtech startup developing a minimally‑invasive device for treating heart failure by synchronizing heart and lung function using the body’s “respiratory pump.” | https://www.levron-medical.com/

4. [LinkedIn, 2026] Shimon Eckhouse is the founder and owner of Alon MedTech Ventures. | https://www.linkedin.com/in/shimon-eckhouse

5. [Frontiers in Cardiovascular Medicine, 2024] Frontiers | Device therapies for heart failure with reduced ejection fraction: a new era | https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1388232/full

6. [PMC, 2022] A Multistep Approach to Deal With Advanced Heart Failure: A Case Report on the Positive Effect of Cardiac Contractility Modulation Therapy on Pulmonary Pressure Measured by CardioMEMS - PMC | https://pmc.ncbi.nlm.nih.gov/articles/PMC9013826/